At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 50 enrolled

Drug / intervention

ABI-007 +1 moredrug

Likely dose

ABI-007 125 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00394082

NCT00394082Phase 2Completed

Compare CT.gov

A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Celgene·interventional·Posted Oct 31, 2006·Updated Nov 25, 2019

In Brief

A Phase 2 clinical trial evaluating ABI-007 and Bevacizumab for Metastatic Breast Cancer. Completed, enrolled 50 participants across 20 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMetastatic Breast Cancer

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJun 2006

First PostedOct 2006

Primary CompletionSep 2009

Study CompletionFeb 2011

TodayJul 2026

First PostedOct 31, 2006

Enrollment StartJun 1, 2006

Primary CompletionSep 1, 2009

Study CompletionFeb 1, 2011

TodayJul 2, 2026

Enrollment to primary: 3.3 yearsPosted 19.7 years ago

Interventions

ABI-007drug

125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.

Bevacizumabdrug

Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.